Summary
235.05 -1.19(-0.50%)09/06/2024
CoreSite Realty Corporation (COR)
CoreSite Realty Corporation (COR)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.51 | -1.89 | -2.00 | -0.70 | 0.16 | 34.92 | 189.47 | 10,346.67 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 235.05 | |
| Open | 236.36 | |
| High | 237.43 | |
| Low | 233.32 | |
| Volume | 1,279,627 | |
| Change | -1.20 | |
| Change % | -0.51 | |
| Avg Volume (20 Days) | 926,359 | |
| Volume/Avg Volume (20 Days) Ratio | 1.38 | |
| 52 Week Range | 171.65 - 247.64 | |
| Price vs 52 Week High | -5.08% | |
| Price vs 52 Week Low | 36.94% | |
| Range | -0.55 | |
| Gap Up/Down | -2.03 | |
Fundamentals | ||
| Market Capitalization (Mln) | 46,300 | |
| EBIDTA | 3,418,519,040 | |
| PE Ratio | 23.3854 | |
| PEG Ratio | 1.5767 | |
| WallStreet Target Price | 212.25 | |
| Book Value | 3.3940 | |
| Earnings Per Share | 8.2000 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 11.9300 | |
| EPS Estimate Next Year | 12.8700 | |
| Diluted EPS (TTM) | 8.2000 | |
| Revenues | ||
| Profit Marging | 0.0066 | |
| Operating Marging (TTM) | 0.0092 | |
| Return on asset (TTM) | 0.0270 | |
| Return on equity (TTM) | 2.3366 | |
| Revenue TTM | 254,425,235,456 | |
| Revenue per share TTM | 1,247.2940 | |
| Quarterly Revenue Growth (YOY) | 0.1150 | |
| Quarterly Earnings Growth (YOY) | 0.2240 | |
| Gross Profit (TTM) | 8,334,565,000 | |
| Dividends | ||
| Dividend Share | 1.9150 | |
| Dividend Yield | 0.0104 | |
| Valuations | ||
| Trailing PE | 23.3854 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 200,854,000 | |
| Shares Float | 169,543,834 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.04 | |
| Insider (%) | 16.68 | |
| Institutions (%) | 78.92 | |
09/06 06:00 EST - accesswire.com
Camino and Nittetsu Extend Again by One Additional Week Exclusive Rights to Negotiate Copper Mine Acquisition in Chile
VANCOUVER, BC / ACCESSWIRE / September 6, 2024 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) (WKN:A116E1) ("Camino" or the "Company") and Nittetsu Mining Co., Ltd. ("Nittetsu") announce a one-week extension to their exclusive rights to finalize negotiations and documentation for the acquisition of the Puquios Project (the "Proposed Acquisition"), a construction-ready copper mine located in Chile (see news release dated June 27, 2024).
Camino and Nittetsu Extend Again by One Additional Week Exclusive Rights to Negotiate Copper Mine Acquisition in Chile
VANCOUVER, BC / ACCESSWIRE / September 6, 2024 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) (WKN:A116E1) ("Camino" or the "Company") and Nittetsu Mining Co., Ltd. ("Nittetsu") announce a one-week extension to their exclusive rights to finalize negotiations and documentation for the acquisition of the Puquios Project (the "Proposed Acquisition"), a construction-ready copper mine located in Chile (see news release dated June 27, 2024).
08/30 12:37 EST - zacks.com
Why Is Cencora (COR) Down 2.8% Since Last Earnings Report?
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
Why Is Cencora (COR) Down 2.8% Since Last Earnings Report?
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
08/30 10:41 EST - zacks.com
Here's Why Cencora (COR) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Cencora (COR) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
08/30 06:00 EST - accesswire.com
Camino and Nittetsu Extend by One Week Exclusive Rights to Negotiate Copper Mine Acquisition in Chile
VANCOUVER, BC / ACCESSWIRE / August 30, 2024 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF)(WKN:A116E1) (" Camino " or the " Company ") and Nittetsu Mining Co., Ltd. (" Nittetsu ") announce a one-week extension to their exclusive rights to finalize negotiations and documentation for the acquisition of the Puquios Project (the " Proposed Acquisition "), a construction-ready copper mine located in Chile (see news release dated June 27, 2024 ).
Camino and Nittetsu Extend by One Week Exclusive Rights to Negotiate Copper Mine Acquisition in Chile
VANCOUVER, BC / ACCESSWIRE / August 30, 2024 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF)(WKN:A116E1) (" Camino " or the " Company ") and Nittetsu Mining Co., Ltd. (" Nittetsu ") announce a one-week extension to their exclusive rights to finalize negotiations and documentation for the acquisition of the Puquios Project (the " Proposed Acquisition "), a construction-ready copper mine located in Chile (see news release dated June 27, 2024 ).
08/23 10:59 EST - seekingalpha.com
Is Walgreens Ready To Rebound?
Walgreens issued $750 million in senior unsecured notes at 8.125%, refinancing 3.800% notes due in 2024, leading to a $32.4 million increase in annual interest costs. Walgreens sold its remaining Cencora shares for $1.1 billion, with a potential $55 million annual interest expense savings, reducing its ownership in Cencora from 12% to 10%. The $750 million raised will primarily reduce Walgreens' existing debt, signaling confidence in handling higher debt servicing costs. The funds will also be allocated for potential growth investments.
Is Walgreens Ready To Rebound?
Walgreens issued $750 million in senior unsecured notes at 8.125%, refinancing 3.800% notes due in 2024, leading to a $32.4 million increase in annual interest costs. Walgreens sold its remaining Cencora shares for $1.1 billion, with a potential $55 million annual interest expense savings, reducing its ownership in Cencora from 12% to 10%. The $750 million raised will primarily reduce Walgreens' existing debt, signaling confidence in handling higher debt servicing costs. The funds will also be allocated for potential growth investments.
08/22 14:16 EST - zacks.com
Cencora (COR) Gains 16.6% YTD: What's Driving the Stock?
Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.
Cencora (COR) Gains 16.6% YTD: What's Driving the Stock?
Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.
08/22 10:46 EST - zacks.com
Why Cencora (COR) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Cencora (COR) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
08/21 08:25 EST - zacks.com
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
08/16 10:51 EST - zacks.com
Here's Why Cencora (COR) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Cencora (COR) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
08/14 10:46 EST - zacks.com
Why Cencora (COR) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Cencora (COR) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
08/05 10:15 EST - zacks.com
Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
08/02 13:59 EST - marketwatch.com
Walgreens continues to shed stake in Cencora as it looks to bolster turnaround
Struggling drug-store chain Walgreens Boots Alliance Inc. has sold off shares of drug distributor Cencora Inc., handing the retailer some $1.1 billion in proceeds as it tries to carry out a turnaround plan and pay down debt.
Walgreens continues to shed stake in Cencora as it looks to bolster turnaround
Struggling drug-store chain Walgreens Boots Alliance Inc. has sold off shares of drug distributor Cencora Inc., handing the retailer some $1.1 billion in proceeds as it tries to carry out a turnaround plan and pay down debt.
08/02 13:01 EST - zacks.com
All You Need to Know About Cencora (COR) Rating Upgrade to Buy
Cencora (COR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Cencora (COR) Rating Upgrade to Buy
Cencora (COR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
08/02 10:45 EST - techcrunch.com
Pharma giant Cencora is alerting millions about its data breach
Cencora has so far notified over a million people around the U.S. that their personal and protected health information was compromised in a data breach earlier this year, TechCrunch has found.
Pharma giant Cencora is alerting millions about its data breach
Cencora has so far notified over a million people around the U.S. that their personal and protected health information was compromised in a data breach earlier this year, TechCrunch has found.
08/01 19:29 EST - forbes.com
Walgreens Sells Another Stake In Distributor Cencora For $1.1 Billion
Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $1.1 billion, which will be used “primarily for debt paydown and general corporate purposes.”
Walgreens Sells Another Stake In Distributor Cencora For $1.1 Billion
Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $1.1 billion, which will be used “primarily for debt paydown and general corporate purposes.”
08/01 18:20 EST - reuters.com
Walgreens further reduces stake in Cencora
Walgreens Boots Alliance said on Thursday it has sold shares in drug distributor Cencora for proceeds of about $1.1 billion.
Walgreens further reduces stake in Cencora
Walgreens Boots Alliance said on Thursday it has sold shares in drug distributor Cencora for proceeds of about $1.1 billion.
07/31 21:30 EST - zacks.com
Compared to Estimates, Cencora (COR) Q3 Earnings: A Look at Key Metrics
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Compared to Estimates, Cencora (COR) Q3 Earnings: A Look at Key Metrics
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
07/31 18:14 EST - reuters.com
Cencora says additional data stolen in February cyberattack
U.S. drug distributor Cencora said on Wednesday additional data on patients, beyond what was initially identified, had been stolen in a cyberattack and data breach that happened in February.
Cencora says additional data stolen in February cyberattack
U.S. drug distributor Cencora said on Wednesday additional data on patients, beyond what was initially identified, had been stolen in a cyberattack and data breach that happened in February.
07/31 14:57 EST - zacks.com
Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised
Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.
Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised
Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.
07/31 11:12 EST - seekingalpha.com
Cencora, Inc. (COR) Q3 2024 Earnings Call Transcript
Cencora, Inc. (NYSE:COR ) Q3 2024 Earnings Conference Call July 31, 2024 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President, Head of Investor Relations & Treasury Steve Collis - Chairman, President & Chief Executive Officer Bob Mauch - Executive Vice President & Chief Operating Officer Jim Cleary - Executive Vice President & Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI Allen Lutz - Bank of America Eric Percher - Nephron Research Charles Rhyee - TD Cowen Erin Wright - Morgan Stanley Daniel Grosslight - Citi George Hill - Deutsche Bank Stephanie Davis - Barclays Eric Coldwell - Baird Kevin Caliendo - UBS Operator Good morning and good afternoon, ladies and gentlemen. Welcome to the Cencora Q3 Earnings Call.
Cencora, Inc. (COR) Q3 2024 Earnings Call Transcript
Cencora, Inc. (NYSE:COR ) Q3 2024 Earnings Conference Call July 31, 2024 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President, Head of Investor Relations & Treasury Steve Collis - Chairman, President & Chief Executive Officer Bob Mauch - Executive Vice President & Chief Operating Officer Jim Cleary - Executive Vice President & Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI Allen Lutz - Bank of America Eric Percher - Nephron Research Charles Rhyee - TD Cowen Erin Wright - Morgan Stanley Daniel Grosslight - Citi George Hill - Deutsche Bank Stephanie Davis - Barclays Eric Coldwell - Baird Kevin Caliendo - UBS Operator Good morning and good afternoon, ladies and gentlemen. Welcome to the Cencora Q3 Earnings Call.